DURECT CORP Form 8-K May 18, 2015

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### Form 8-K

## **Current Report**

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

May 18, 2015

**Date of Report** 

(Date of earliest event reported)

## **DURECT CORPORATION**

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of

**000-31615** (Commission

94-3297098 (I.R.S. Employer

incorporation or organization)

File Number)

**Identification No.)** 

## Edgar Filing: DURECT CORP - Form 8-K

### 10260 Bubb Road

## Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 8.01 Other Events**

On May 18, 2015, DURECT Corporation, a Delaware corporation ( DURECT ), issued a press release announcing that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT s Epigenomic Regulator Program. A copy of DURECT s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

### **Item 9.01 Financial Statements and Exhibits**

- (d) Exhibits
- 99.1 Press Release of DURECT Corporation dated May 18, 2015

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 18, 2015

# **DURECT Corporation**

By: /s/ James E. Brown James E. Brown

President and Chief Executive Officer

# INDEX TO EXHIBITS

Exhibit	
---------	--

**Number** Description

99.1 Press Release of DURECT Corporation dated May 18, 2015